Paloma Partners’s AstraZeneca AZN Stock Holding History

Paloma Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-20,000	Closed	-$1.41M	–	1190
2014 Q4	$1.41M	Buy	+20,000	New	+$1.43M	0.06%	333

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paloma Partners's AZN Position: Q4 2019 in Review

Paloma Partners sold out of AstraZeneca (AZN) in Q4 2019, closing a stake of 2,656 shares — an estimated $237K sold.

Paloma Partners first reported a position in AZN in Q1 2014 and held it in 7 quarters. The position peaked at $3.72M in Q2 2014. 634 funds tracked by Wall St. Rank hold AZN as of Q4 2019.

Paloma Partners reported no remaining AstraZeneca position as of Q4 2019 after selling out during the quarter.
Paloma Partners sold 2,656 AstraZeneca shares in Q4 2019, an estimated $237K.
Paloma Partners first reported a position in AstraZeneca in Q1 2014 and held it in 7 quarters.
Paloma Partners's AstraZeneca position peaked at $3.72M in Q2 2014.
634 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.